Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program
Boehringer Ingelheim today announced the execution of the agreement on the acquisition of Labor Dr. Merk & Kollegen. The acquisition will enable Boehringer Ingelheim to further expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP) platform and cancer vaccines platforms. Labor Dr. Merk & Kollegen has outstanding experience in process development, manufacturing and analytical characterization in virology besides expertise in microbiology and cell culture. Labor Dr. Merk & Kollegen has already worked in close collaboration with Boehringer Ingelheim on viral-based therapy development since 2015.
“The acquisition of Labor Dr. Merk & Kollegen is strengthening our promising pipeline with diverse potential first-in-class cancer immunology and cancer cell directed therapies for patients with hard-to-treat cancer,” said Dr. Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit. “The trusting and highly effective collaboration between our scientists and the Labor Dr. Merk & Kollegen team has already contributed significantly to our progress in viral-based cancer therapies. We will welcome the Labor Dr. Merk & Kollegen team and look forward to jointly advancing our program in this area.”
Boehringer Ingelheim is taking cancer on by strengthening its position in cancer immunology, with a focus on cancer vaccines, oncolytic viruses, T-cell engagers, stromal modulators and myeloid cell modulators by combining its world-class, in-house research and development with that of highly innovative external companies. The addition of Labor Dr. Merk & Kollegen’s site will enable Boehringer Ingelheim to further strengthen its oncolytic virus and cancer vaccine development capabilities and capacities by establishing an end-to-end fully integrated center of excellence for virus development and clinical manufacturing. It will add to a series of strategic acquisitions and collaborations over the past years, including the acquisition of ViraTherapeutics and AMAL Therapeutics, which are contributing assets that will be further developed at Labor Dr. Merk & Kollegen’s site.
Labor Dr. Merk & Kollegen is a privately-held company founded in 1971. It is headquartered in Ochsenhausen, Germany, close to Boehringer Ingelheim’s Biberach R&D site. As a center of excellence in virology, Labor Dr. Merk & Kollegen has a long track record in GLP and GMP certified biosafety testing. In recent years Labor Dr. Merk & Kollegen established its GMP-virus manufacturing facility. With around 130 highly qualified and specialized employees, the company has built considerable expertise in process development, manufacturing and analytical characterization of viral therapeutics and oncolytic viral therapeutics. Labor Dr. Merk & Kollegen will be integrated with all employees as a new unit into Boehringer Ingelheim’s Development organization and continue to operate at its Ochsenhausen site. A future expansion is planned.
“Following our successful strategic partnership, we are really excited to join forces with Boehringer Ingelheim,” said Dr. Ingrid Rapp, CEO at Labor Dr. Merk & Kollegen. “Boehringer Ingelheim is a truly global pharmaceutical company with excellent R&D capacities. We look forward to taking our next development step in oncology as part of this outstanding team.”
The companies did not disclose the financial terms of the deal. The transaction is subject to the approval of the competition authorities in Germany. Closing will follow thereafter.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/agreement-acquire-labor-dr-merk
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005383/en/
Contact information
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
press@boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Declares Dividend for Fourth Quarter 202530.10.2025 22:15:00 EET | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on January 9, 2026 to shareholders of record as of December 19, 2025. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20251030551985/en/
Rimini Street Announces Fiscal Third Quarter 2025 Financial and Operating Results30.10.2025 22:01:00 EET | Press release
Rimini Street, Inc. (the “Company”) (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal third quarter ended September 30, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030625900/en/ Rimini Street Announces Fiscal Third Quarter 2025 Financial and Operating Results Select Third Quarter 2025 Financial Results Revenue was $103.4 million for the third quarter of 2025, a decrease of 1.2% compared to $104.7 million for the same period last year; excluding the wind down of support services for Oracle’s PeopleSoft software products, the revenue increased by 2.5%. U.S. revenue was $46.3 million for the third quarter of 2025, a decrease of 10.3% compared to $51.6 million for the same period last year; excluding the wind down
Canva Launches Creative Operating System30.10.2025 19:00:00 EET | Press release
Canva, the world’s only all-in-one visual communication platform, today announced the launch of its Creative Operating System, marking the biggest evolution of its product to date. The launch brings together over a decade of innovation alongside a suite of new products designed to supercharge creativity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030695119/en/ Built on Canva’s world-first Design Model, the Creative Operating System brings together every part of the creative process from design and collaboration to publishing and performance. Built on Canva’s world-first Design Model, the Creative Operating System brings together every part of the creative process from design and collaboration to publishing and performance. The result is a faster, smarter, and more connected way to design, where human creativity leads and AI amplifies what’s possible. With more than 260 million monthly active users, $3.5 billion in ann
Svante Celebrates 18 Years of Carbon Management Innovation with Historic Milestones in 202530.10.2025 18:25:00 EET | Press release
Svante Technologies Inc. (Svante), a global leader in carbon capture and removal solutions, proudly marks its 18th anniversary this month, celebrating nearly two decades of pioneering industrial carbon management technology. This year has been one of the most transformative in Svante’s history, defined by bold innovation, strategic partnerships, and the commissioning of the world’s first commercial manufacturing facility for solid sorbent-based carbon capture and removal filters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030974500/en/ Founded in 2007 with a vision to revolutionize how the world manages carbon dioxide emissions, Svante has grown into a cornerstone of the global carbon management industry. In 2025, that vision took a monumental leap forward with the launch of the Redwood Facility in Burnaby, BC — a 141,000-square-foot Centre of Excellence for Carbon Capture and Removal. This first-of-its-kind manufactu
Ireland Unveils Seven New Halloween Experiences30.10.2025 16:00:00 EET | Press release
With seven brand-new Halloween hubs or experiences launching across the island this month, Ireland has truly become the ultimate destination to celebrate Halloween in 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022209535/en/ Derry Halloween Festival, County Derry~Londonderry Ireland’s Halloween Season Rooted in the ancient Celtic festival of Samhain, Halloween originated in Ireland more than 2,000 years ago and, this year, the island of Ireland is expanding its celebration like never before. With over 340 events planned across the island to celebrate this year, Halloween in Ireland is fast becoming a bucket-list travel experience. Seven new Halloween hubs join existing flagship events across the island of Ireland including the Púca Festival in County Meath and Derry Halloween in Derry-Londonderry which together welcomed over 169,000 visitors last year. The seven new hubs are inviting visitors to come and explore
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom